Group 1 - The pharmaceutical sector led the market today, with significant gains in medical services and CRO concepts, as evidenced by the rise in various indices [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index and the CSI Biotech Theme Index both increased by 1.9%, while the CSI 300 Pharmaceutical Health Index rose by 1.7% [1] - Active trading was noted in related ETFs, with the Hong Kong Stock Connect Innovative Drug ETF (159316) and the Pharmaceutical ETF (512010) achieving transaction volumes of 820 million and 1.09 billion respectively, indicating increased market activity [1] Group 2 - According to Zhongtai Securities, multiple factors are driving a gradual recovery in demand for CRO and CDMO within the pharmaceutical sector, alongside a continuous supply-side clearance over the past three years [1] - The sector is expected to experience a "Davis Double Play," where both profitability and valuation are anticipated to improve [1]